http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 05 Mar 2026 06:52:34 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Bright+Minds+Biosciences+Inc.+%28DRUG%29+PT+Raised+to+%24145+at+H.C.+Wainwright/26114780.html (Updated - March 5, 2026 6:52 AM EST) <p>H.C. Wainwright analyst Pat Trucchio raised the price target on Bright Minds Biosciences Inc. (NASDAQ: DRUG) to $145.00 (from $115.00) while maintaining a Buy rating.</p><p>The analyst commented: "On March 3, we caught up with Bright Minds management including CEO Ian McDonald, CSO Jan Torleif Pedersen, and CMO Stephen D. Collins to discuss the BREAKTHROUGH Phase 2 data, released on January 6, as well as the expected development pathway forward and emerging product profile for lead candidate BMB-101, a G-protein–biased 5-HT2C agonist engineered to avoid beta-arrestin recruitment and reduce the risk of tolerance. The http://www.streetinsider.com/Analyst+PT+Change/Bright+Minds+Biosciences+Inc.+%28DRUG%29+PT+Raised+to+%24145+at+H.C.+Wainwright/26114780.html Thu, 05 Mar 2026 06:52:34 +0000 DRUG http://www.streetinsider.com/Analyst+Comments/Bright+Minds+Biosciences+Inc.+%28DRUG%29+PT+Raised+to+%24145+at+H.C.+Wainwright/26114780.html (Updated - March 5, 2026 6:52 AM EST) <p>H.C. Wainwright analyst Pat Trucchio raised the price target on Bright Minds Biosciences Inc. (NASDAQ: DRUG) to $145.00 (from $115.00) while maintaining a Buy rating.</p><p>The analyst commented: "On March 3, we caught up with Bright Minds management including CEO Ian McDonald, CSO Jan Torleif Pedersen, and CMO Stephen D. Collins to discuss the BREAKTHROUGH Phase 2 data, released on January 6, as well as the expected development pathway forward and emerging product profile for lead candidate BMB-101, a G-protein–biased 5-HT2C agonist engineered to avoid beta-arrestin recruitment and reduce the risk of tolerance. The http://www.streetinsider.com/Analyst+Comments/Bright+Minds+Biosciences+Inc.+%28DRUG%29+PT+Raised+to+%24145+at+H.C.+Wainwright/26114780.html Thu, 05 Mar 2026 06:52:34 +0000 DRUG http://www.streetinsider.com/Press+Releases/Bright+Minds+Biosciences+to+Present+at+Upcoming+Conferences/26060620.html <p>NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:15%; width:15%; min-width:15%;"><strong>EVENT:</strong></td><td style="max-width:85%; width:85%; min-width:85%;">TD Cowen 46th Annual Health Care Conference</td></tr><tr><td><strong>DATE:</strong></td><td>Wednesday, March 4, 2026</td></tr><tr><td><strong>TIME:</strong></td><td>9:10am ET</td></tr><tr><td><strong>WEBCAST:</strong></td><td><a href="https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/cy8oQuZ2XnJiLiEqXopBn7" rel="nofollow" target="_blank"><strong>https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/cy8oQuZ2XnJiLiEqXopBn7</strong></a></td></tr><tr><td colspan="2"> </td></tr><tr><td><strong>EVENT: <br /></strong></td><td>Leerink Partners 2026 Global Healthcare Conference<strong><br /></strong></td></tr><tr><td><strong>DATE: <br /></strong></td><td>Monday, March 9, 2026<strong><br http://www.streetinsider.com/Press+Releases/Bright+Minds+Biosciences+to+Present+at+Upcoming+Conferences/26060620.html Wed, 25 Feb 2026 16:30:00 +0000 DRUG http://www.streetinsider.com/Globe+Newswire/Bright+Minds+Biosciences+to+Present+at+Upcoming+Conferences/26060620.html <p>NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:15%; width:15%; min-width:15%;"><strong>EVENT:</strong></td><td style="max-width:85%; width:85%; min-width:85%;">TD Cowen 46th Annual Health Care Conference</td></tr><tr><td><strong>DATE:</strong></td><td>Wednesday, March 4, 2026</td></tr><tr><td><strong>TIME:</strong></td><td>9:10am ET</td></tr><tr><td><strong>WEBCAST:</strong></td><td><a href="https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/cy8oQuZ2XnJiLiEqXopBn7" rel="nofollow" target="_blank"><strong>https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/cy8oQuZ2XnJiLiEqXopBn7</strong></a></td></tr><tr><td colspan="2"> </td></tr><tr><td><strong>EVENT: <br /></strong></td><td>Leerink Partners 2026 Global Healthcare Conference<strong><br /></strong></td></tr><tr><td><strong>DATE: <br /></strong></td><td>Monday, March 9, 2026<strong><br http://www.streetinsider.com/Globe+Newswire/Bright+Minds+Biosciences+to+Present+at+Upcoming+Conferences/26060620.html Wed, 25 Feb 2026 16:30:00 +0000 DRUG http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26013988.html si-local-file:///var/storage/secattach/20260217/26013988.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26013988.html Tue, 17 Feb 2026 16:35:00 +0000 DRUG DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26013988.html si-local-file:///var/storage/secattach/20260217/26013988.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26013988.html Tue, 17 Feb 2026 16:35:00 +0000 DRUG DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26013988.html si-local-file:///var/storage/secattach/20260217/26013988.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26013988.html Tue, 17 Feb 2026 16:35:00 +0000 DRUG DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Commodore+Capital+LP/26013481.html si-local-file:///var/storage/secattach/20260217/26013481.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Commodore+Capital+LP/26013481.html Tue, 17 Feb 2026 16:23:00 +0000 DRUG DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Commodore+Capital+LP/26013481.html si-local-file:///var/storage/secattach/20260217/26013481.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Commodore+Capital+LP/26013481.html Tue, 17 Feb 2026 16:23:00 +0000 DRUG DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Commodore+Capital+LP/26013481.html si-local-file:///var/storage/secattach/20260217/26013481.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Commodore+Capital+LP/26013481.html Tue, 17 Feb 2026 16:23:00 +0000 DRUG DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26012002.html si-local-file:///var/storage/secattach/20260217/26012002.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26012002.html Tue, 17 Feb 2026 16:00:00 +0000 DRUG DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26012002.html si-local-file:///var/storage/secattach/20260217/26012002.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26012002.html Tue, 17 Feb 2026 16:00:00 +0000 DRUG DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26012002.html si-local-file:///var/storage/secattach/20260217/26012002.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26012002.html Tue, 17 Feb 2026 16:00:00 +0000 DRUG DRUG O.53098441